SCH: Personalized Rescheduling of Adaptive Radiation Therapy for Head & Neck Cancer
SCH:头部适应性放射治疗的个性化重新安排
基本信息
- 批准号:10628045
- 负责人:
- 金额:$ 24.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptionAffectAgingAlgorithmsAnatomyAreaBehaviorCancer ControlCapitalClinicalClinical DataClinical TreatmentCommunitiesCommunity HospitalsComplicationComputer softwareCoupledDataData SetDecision MakingDecision Support SystemsDevelopmentDevicesDiagnosisDoseEconomicsEmerging TechnologiesEnvironmentEquipmentEvaluationEvolutionGoalsHead CancerHead and Neck CancerHead and neck structureHealthHealth PolicyHealth TechnologyHealthcareHumanHuman ResourcesImageIncentivesIndividualInstructionInsurance CarriersInterventionLifeLinear Accelerator Radiotherapy SystemsMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of larynxMalignant neoplasm of pharynxMedical DeviceMedicareMethodologyMethodsModelingModernizationMonitorMorbidity - disease rateNeck CancerNormal tissue morphologyOperations ResearchOrganOutcomeOverdosePatient CarePatient imagingPatientsPhysiciansPoliciesProbabilityProcessPropertyProviderRadiationRadiation therapyRegimenResearchResourcesRiskSMART healthScheduleScienceSelf-Help DevicesSeriesSoftware ToolsStructureSurvivorsSystemSystems IntegrationTechniquesTechnologyTimeToxic effectTumor VolumeUncertain RiskUncertaintyValidationVariantWorkadvanced analyticsbasecancer radiation therapychemoradiationclinical implementationconnected healthcostdesignevidence basehead and neck cancer patientimage guided radiation therapyimprovedin silicoindividual patientindividualized medicineinnovationinsightlow and middle-income countriesmalignant mouth neoplasmmodels and simulationmultidisciplinarynew technologynext generationnovelprogramsprototyperadiation-induced injuryresponserisk stratificationside effectsoft tissuestandard caresupport toolstheoriestooltreatment planningtreatment responsetreatment stratificationtumor
项目摘要
Head and neck cancers (HNCs) account for nearly 3% of all cancers in the U.S. and most
commonly affect aging individuals. While chemo-radiotherapy is the standard treatment
approach for HNC, the method is known to cause substantial side-effects. In particular,
anatomical changes occurring during the treatment may result in under-coverage of the clinical
target volume or over-dosage of organs at risk.
The project will develop novel optimization models for Adaptive Radiation Therapy (ART) – a
customized treatment planning approach for individual patients designed by evaluating the
systematic and random variations in tumor response. The models will use imaging data of tumor
volume and normal tissue complication probabilities to determine the optimal number and timing
of treatment replans. The models will provide personalized optimization through sequential
decision-making based on response to treatment, as well as optimization and evaluation of
simple threshold replanning policies often used by doctors. Optimal behavior in the face of
conflicting payer/provider perspectives for emerging technologies will also be analyzed using
mechanism design techniques. ART requires information about patient-state as well as transition
probabilities describing the tumor's evolution over time. Since the process inherently calls for
sequential decision-making under uncertainty, the proposed optimization models use a Markov
Decision Process (MDP). The resulting optimal policies may be difficult to implement in practice,
especially in centers lacking state-of-the-art equipment. Therefore, the proposed work will further
evaluate simple threshold replanning policies using a bilevel programming framework. In
particular, the bilevel program will find threshold values for various patient classes by minimizing
the deviation from the MDP-prescribed policy.
The proposed framework offers multiple avenues for methodological contributions. The novel
MDP design framework is an incredibly powerful tool that can be used to model many
interesting questions. We will explore ways of discretizing the continuous state spaces and
estimating transition probabilities based on patient imaging data. We will explore algorithms for
solving bilevel programs, especially utilizing the structure and properties of the lower-level MDP
models. Finally, we will study applications of the principal-agent framework from economics in
modeling payer/provider interactions for emerging clinical therapies.
RELEVANCE (See instructions):
This study uses novel models to develop and validate an integrated approach to reduce cancer
radiotherapy side effects while maintaining or improving cancer control. It will maximize efficiency for
patients and providers. Its findings will inform decisions about individual radiation planning, optimize risk-
stratified treatment, and healthcare policy implementation of effective new technology interventions.
头颈部癌症(HNC)占美国所有癌症的近3%,而且大多数
通常影响到年老的人。而化疗和放射治疗是标准的治疗方法
对于HNC的方法,该方法已知会引起巨大的副作用。特别是,
在治疗过程中发生的解剖变化可能会导致临床报道不足。
危险器官的靶量或过量。
该项目将为自适应放射治疗(ART)开发新的优化模型
为个别患者设计的个性化治疗计划方法,通过评估
肿瘤反应的系统性和随机性变化。这些模型将使用肿瘤的成像数据
确定最佳数量和时机的体积和正常组织并发症概率
重新制定治疗计划。这些模型将通过顺序提供个性化的优化
以治疗反应为基础的决策,以及对
医生经常使用的简单门槛重新规划政策。面对最优行为
还将使用以下工具分析新兴技术的支付方/提供商观点冲突
机械设计技术。ART需要有关患者状态和转换的信息
描述肿瘤随时间演变的概率。因为该过程本身就需要
不确定条件下的序贯决策问题,提出了基于马尔可夫模型的优化模型
决策过程(MDP)。所得到的最优策略可能难以在实践中实现,
尤其是在缺乏最先进设备的中心。因此,拟议的工作将进一步
使用双层规划框架评估简单的门槛重新规划政策。在……里面
具体地说,双层程序将通过最小化为各种患者类别找到阈值
偏离MDP规定的政策。
拟议的框架为方法学贡献提供了多种途径。这部小说
MDP设计框架是一个令人难以置信的强大工具,可以用来对许多
有趣的问题。我们将探索离散化连续状态空间的方法,并
基于患者成像数据估计转移概率。我们将探索以下算法:
求解两层规划,特别是利用低层MDP的结构和性质
模特们。最后,我们将从经济学的角度研究委托代理框架的应用。
为新出现的临床疗法建立付款人/提供者互动模型。
相关性(请参阅说明):
这项研究使用新的模型来开发和验证减少癌症的综合方法。
放射治疗的副作用,同时维持或改善癌症控制。它将最大限度地提高
患者和提供者。它的发现将为个人放射计划的决策提供依据,优化风险-
分层治疗,实施有效的新技术干预的医疗保健政策。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Clifton David Fuller其他文献
Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials
第三阶段转移性实体瘤试验中的非方案放疗
- DOI:
10.1016/j.ijrobp.2024.05.033 - 发表时间:
2024-12-01 - 期刊:
- 影响因子:6.500
- 作者:
Alexander D. Sherry;Timothy A. Lin;Zachary R. McCaw;Esther J. Beck;Ramez Kouzy;Joseph Abi Jaoude;Adina H. Passy;Avital M. Miller;Gabrielle S. Kupferman;Clifton David Fuller;Charles R. Thomas;Eugene J. Koay;Chad Tang;Pavlos Msaouel;Ethan B. Ludmir - 通讯作者:
Ethan B. Ludmir
International Expert-Based Consensus Definition, Classification Criteria, and Minimum Data Elements for Osteoradionecrosis of the Jaw: An Interdisciplinary Modified Delphi Study
基于国际专家共识的颌骨放射性骨坏死定义、分类标准及最低数据要素:一项跨学科改良德尔菲研究
- DOI:
10.1016/j.ijrobp.2024.12.017 - 发表时间:
2025-06-01 - 期刊:
- 影响因子:6.500
- 作者:
Amy C. Moreno;Erin E. Watson;Laia Humbert-Vidan;Douglas E. Peterson;Lisanne V. van Dijk;Teresa Guerrero Urbano;Lisa Van den Bosch;Andrew J. Hope;Matthew S. Katz;Frank J.P. Hoebers;Ruth A. Aponte Wesson;James E. Bates;Paolo Bossi;Adeyinka F. Dayo;Mélanie Doré;Eduardo Rodrigues Fregnani;Thomas J. Galloway;Daphna Y. Gelblum;Issa A. Hanna;Christina E. Henson;Clifton David Fuller - 通讯作者:
Clifton David Fuller
62 Operational Ontology for Radiation Oncology (OORO) - a Professional Society-Based, Multi-Stakeholder Consensus Driven Informatics Standard Supporting Clinical and Research Use of Real-World Data
62 放射肿瘤学操作本体论(OORO)——一个基于专业协会、多方利益相关者共识驱动的信息学标准,支持现实世界数据的临床和研究使用
- DOI:
10.1016/s0167-8140(23)89948-0 - 发表时间:
2023-09-01 - 期刊:
- 影响因子:5.300
- 作者:
Charles Mayo;Clifton David Fuller;Mary Feng;Kristy Brock;Randi Kudner;Peter Balter;Jeffrey Buchsbaum;Amanda Caissie;Elizabeth Covington;Emily Daugherty;David Sup Hong;Andra Krauze;Jon Kruse;Todd McNutt;Richard Popple;Susan Richardson;Jatinder Palta;Thomas Purdie;Lawrence Tarbox;Ying Xiao - 通讯作者:
Ying Xiao
191 Dose prescription variability in Oropharynx Cancer Radiotherapy
- DOI:
10.1016/s0167-8140(24)00538-3 - 发表时间:
2024-03-01 - 期刊:
- 影响因子:
- 作者:
Christian R Hansen;Tony Tadic;Andrea McNiven;Jens Petersen;Sharma Manju;Gareth Price;Mohamed A Naser;Pernille Lassen;Jens Overgaard;Lachlan McDowell;Clifton David Fuller;David Thomsen;Sue S Yom;J⊘rgen Johansen;Jeppe Friborg;Andrew Hope - 通讯作者:
Andrew Hope
Clifton David Fuller的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Clifton David Fuller', 18)}}的其他基金
Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-Enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)
动态对比增强 MRI 的定量成像生物标志物前瞻性验证作为放射治疗后口腔牙齿损伤的指标 (QI-ProVE-MRI)
- 批准号:
10668570 - 财政年份:2023
- 资助金额:
$ 24.72万 - 项目类别:
Diversity Supplement: SCH: Personalized Rescheduling of Adaptive Radiation Therapy for Head and Neck Cancer
多样性补充:SCH:头颈癌适应性放射治疗的个性化重新安排
- 批准号:
10599546 - 财政年份:2021
- 资助金额:
$ 24.72万 - 项目类别:
SCH: Personalized Rescheduling of Adaptive Radiation Therapy for Head & Neck Cancer
SCH:头部适应性放射治疗的个性化重新安排
- 批准号:
10397692 - 财政年份:2021
- 资助金额:
$ 24.72万 - 项目类别:
SCH: Personalized Rescheduling of Adaptive Radiation Therapy for Head & Neck Cancer
SCH:头部适应性放射治疗的个性化重新安排
- 批准号:
10737817 - 财政年份:2021
- 资助金额:
$ 24.72万 - 项目类别:
Diversity Supplement: SCH: Personalized Rescheduling of Adaptive Radiation Therapy for Head and Neck Cancer
多样性补充:SCH:头颈癌适应性放射治疗的个性化重新安排
- 批准号:
10599545 - 财政年份:2021
- 资助金额:
$ 24.72万 - 项目类别:
SCH: Personalized Rescheduling of Adaptive Radiation Therapy for Head & Neck Cancer
SCH:头部适应性放射治疗的个性化重新安排
- 批准号:
10737816 - 财政年份:2021
- 资助金额:
$ 24.72万 - 项目类别:
Administrative Supplement to Support Collaborations to Improve AIML-Readiness of NIH-Supported Data for Parent Award SCH: Personalized Rescheduling of Adaptive Radiation Therapy for Head & Neck Cancer
支持合作的行政补充,以提高 NIH 支持的家长奖数据的 AIML 就绪性 SCH:头部自适应放射治疗的个性化重新安排
- 批准号:
10594327 - 财政年份:2021
- 资助金额:
$ 24.72万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 24.72万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 24.72万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 24.72万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 24.72万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 24.72万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 24.72万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 24.72万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 24.72万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 24.72万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 24.72万 - 项目类别:
Standard Grant